دورية أكاديمية
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
| العنوان: | Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study. |
|---|---|
| المؤلفون: | Kogame N; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; Department of Cardiology, Toho University Medical Center Ohashi Hospital, Tokyo, Japan., Guimarães PO; Heart Institute - InCor, University of São Paulo, São Paulo, Brazil., Modolo R; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; Department of Internal Medicine, Cardiology Division, University of Campinas, Campinas, Brazil., De Martino F; Department of Internal Medicine, Discipline of Cardiology, University of Triangulo Mineiro, Uberaba, Brazil., Tinoco J; Instituto Cardiovascular de Linhares LTDA - UNICOR, Linhares, Brazil., Ribeiro EE; Heart Institute - InCor, University of São Paulo, São Paulo, Brazil., Kawashima H; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands., Ono M; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands., Hara H; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands., Wang R; Department of Cardiology, Radboud University, Nijmegen, the Netherlands., Cavalcante R; Boston Scientific, Marlborough, Massachusetts., Moulin B; Associação Evangélica Beneficiente Espírito Santense, Vila Velha, Brazil., Falcão BAA; Hospital Dr. Carlos Alberto Studart Gomes de Messejana, Fortaleza, Brazil., Leite RS; Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia, Porto Alegre, Brazil., de Almeida Sampaio FB; Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil., Morais GR; Hospital Nossa Senhora das Neves, João Pessoa, Brazil., Meireles GC; Hospital do Servidor Público Estadual - IAMSPE, São Paulo, Brazil., Campos CM; Heart Institute - InCor, University of São Paulo, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil., Onuma Y; Department of Cardiology, National University of Ireland Galway, Galway, Ireland., Serruys PW; Department of Cardiology, National University of Ireland Galway, Galway, Ireland; Imperial College London, London, United Kingdom. Electronic address: patrick.w.j.c.serruys@gmail.com., Lemos PA; Heart Institute - InCor, University of São Paulo, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil. Electronic address: pedro.lemos@atscien.com. |
| المصدر: | JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2020 Oct 12; Vol. 13 (19), pp. 2251-2262. Date of Electronic Publication: 2020 Sep 16. |
| نوع المنشور: | Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101467004 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-7605 (Electronic) Linking ISSN: 19368798 NLM ISO Abbreviation: JACC Cardiovasc Interv Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York : Elsevier |
| مواضيع طبية MeSH: | Coronary Artery Disease*, Aspirin ; Drug-Eluting Stents ; Humans ; Percutaneous Coronary Intervention ; Pilot Projects ; Platelet Aggregation Inhibitors ; Prasugrel Hydrochloride ; Treatment Outcome |
| مستخلص: | Objectives: The aim of this study was to evaluate the hypothesis that prasugrel monotherapy following successful everolimus-eluting stent implantation is feasible and safe in patients with stable coronary artery disease (CAD). Background: Recent studies have suggested that short dual-antiplatelet therapy strategies may provide an adequate balance between ischemic and bleeding risks. However, the complete omission of aspirin immediately after percutaneous coronary intervention (PCI) has not been tested so far. Methods: The study was a multicenter, single-arm, open-label trial with a stopping rule based on the occurrence of definite stent thrombosis (if >3, trial enrollment would be terminated). Patients undergoing successful everolimus-eluting stent implantation for stable CAD with SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores <23 were included. All participants were on standard dual-antiplatelet therapy at the time of index PCI. Aspirin was discontinued on the day of the index procedure but given prior to the procedure; prasugrel was administered in the catheterization laboratory immediately after the successful procedure, and aspirin-free prasugrel became the therapy regimen from that moment. Patients were treated solely with prasugrel for 3 months. The primary ischemic endpoint was the composite of cardiac death, spontaneous target vessel myocardial infarction, or definite stent thrombosis, and the primary bleeding endpoint was Bleeding Academic Research Consortium types 3 and 5 bleeding up to 3 months. Results: From February 22, 2018, to May 7, 2019, 201 patients were enrolled. All patients underwent PCI for stable CAD. Overall, 98.5% of patients were adherent to prasugrel at 3-month follow-up. The primary ischemic and bleeding endpoints occurred in 1 patient (0.5%). No stent thrombosis events occurred. Conclusions: Aspirin-free prasugrel monotherapy following successful everolimus-eluting stent implantation demonstrated feasibility and safety without any stent thrombosis in selected low-risk patients with stable CAD. These findings may help underpin larger randomized controlled studies to evaluate the aspirin-free strategy compared with traditional dual-antiplatelet therapy following PCI. (Acetyl Salicylic Elimination Trial: The ASET Pilot Study [ASET]; NCT03469856). (Copyright © 2020. Published by Elsevier Inc.) |
| التعليقات: | Comment in: JACC Cardiovasc Interv. 2020 Oct 12;13(19):2263-2265. (PMID: 32950420) Comment in: JACC Cardiovasc Interv. 2021 Jan 25;14(2):230-231. (PMID: 33478641) Comment in: JACC Cardiovasc Interv. 2021 Jan 25;14(2):230. (PMID: 33478642) |
| فهرسة مساهمة: | Keywords: adjunctive pharmacotherapy; antiplatelet therapy; drug-eluting stent(s); stable coronary artery disease |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03469856 |
| المشرفين على المادة: | 0 (Platelet Aggregation Inhibitors) G89JQ59I13 (Prasugrel Hydrochloride) R16CO5Y76E (Aspirin) |
| تواريخ الأحداث: | Date Created: 20200920 Date Completed: 20210727 Latest Revision: 20210727 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.jcin.2020.06.023 |
| PMID: | 32950419 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1876-7605 |
|---|---|
| DOI: | 10.1016/j.jcin.2020.06.023 |